Marengo Therapeutics

We are thrilled to share updated interim results from our ongoing Phase 2 monotherapy trial with our lead asset, Invikafusp Alfa, in the tissue-agnostic TMB-H cohort at the 2025 Society for Immunotherapy of Cancer (SITC) Meeting. This marks Marengo’s 5th major oral presentation on Invika this year, underscoring continued recognition of the novelty and excitement around our program by the oncology community. This late-breaking oral presentation will highlight not only clinical data but will showcase the translational data from paired biopsies, validating the mechanism of action in the clinic. Join us today, Friday, November 7th, at 11:30 am ET for our oral presentation to hear more. Aurélien Marabelle More information can be found here: https://lnkd.in/eJ82geVw #SITC2025 #Immunotherapy #Oncology #ClinicalTrials

Rounding out a year full of clinical oral presentations, Marengo is thrilled to have been selected for another late-breaking clinical oral presentation at the upcoming 2025 Society for Immunotherapy of Cancer (SITC) meeting. Aurélien Marabelle will share updated Phase 2 monotherapy results from the ongoing STARt-001 trial, which is evaluating Invikafusp alfa in tissue-agnostic, TMB-H solid tumors, including a deeper look into translational data that continues to validate the MOA. The presentation will take place on Friday, November 7, 2025 at 11:30 AM ET. More information here: https://lnkd.in/ehqF2g8C #SITC2025 #Immunotherapy #Oncology #ClinicalTrials #Biotech

Big news from Marengo ahead of Society for Immunotherapy of Cancer (SITC) 2025! We’re excited to share we will present at least five abstracts, including the first public disclosure of TriSTAR0701, our lead program from our TriSTAR T-cell engager platform, targeting Nectin 4, a clinically validated target. Alongside, our collaborators at the National Cancer Institute (NCI) we will feature four preclinical presentations exploring combinations of Invikafusp alfa with standard of care agents including checkpoint inhibitors, chemotherapies, PARP and HDAC inhibitors. Read more 🔗 https://lnkd.in/e5hYZ5dJ #SITC2025 #ImmunoOncology #TriSTAR #Nectin4 #TcellEngager #MarengoTherapeutics

We are honored that Marengo has been selected as a late-breaking oral presentation during the Investigational Immunotherapy session at ESMO - European Society for Medical Oncology 2025. Italiano Antoine will share initial Phase 2 results from the STARt-001 trial, highlighting Invikafusp alfa’s single-agent activity in antigen-rich solid tumors resistant to immune checkpoint blockade, with clinically meaningful single agent activity across multiple major cancer types. This recognition underscores the promise of our next-generation precision immunotherapy approach to address patients with high unmet need. Read more: https://lnkd.in/eumRJ43Z #ESMO25 #Immunotherapy #Oncology #ClinicalTrials #Biotech Zhen Su, MD MBA, Kevin Chin, Ke Liu , MD, PhD

Thrilled to advance our STARt-002 trial into Phase 2 expansion in metastatic breast cancer. This novel combo of invikafusp alfa and TRODELVY® (sacituzumab govitecan-hziy) HCP® is not only able to safely combine but also showing early anti-tumor activity and represents an exciting step forward for patients with HR+/HER2- and TNBC disease. A heartfelt thank you to Gilead Sciences, our investigators, Erika Hamilton, MD, FASCO, Steven Isakoff, Philippe Bedard, Lillian Siu, Aditya Bardia, Kelly Elizabeth McCann, MD, PhD, Anastasia Martynova, M.D., Margaret Gatti-Mays, MD MPH, Virginia Kaklamani, Nathalie LeVasseur and patients for the partnership in driving this important innovation forward. For more information click the link: https://lnkd.in/eqPe_W5q Kevin Chin Zhen Su, MD MBA #BreastCancer #Oncology #Immunotherapy #ClinicalTrials

Marengo is proud and honored to welcome two global leaders: 🔹 Mikael Dolsten, former CSO & President of Worldwide R&D at Pfizer, joins our Board of Directors 🔹 Josep Tabernero MD, PhD Tabernero, world-renowned oncologist and Director of VHIO, joins our high caliber Scientific Advisory Board Their strategic and scientific leadership will be instrumental as we advance clinical development of invikafusp alfa across solid tumors and our pipeline. For more detailed information read:  https://lnkd.in/eqyWhb_p Zhen Su, MD MBA

We’re thrilled to have Jenna Meanor and Angel Lazarov onboard, bringing their incredible expertise, energy, and passion to our mission. We couldn’t be more excited to see the impact they’ll make as part of our growing, dynamic team. Welcome to Marengo, Jenna and Angel — we’re so glad you’re here! 🚀💥 #NewBeginnings #TeamMarengo #Welcome #Biotech #Innovation #MarengoTherapeutics

Marengo is honored to have been selected for an oral presentation at ESMO GI 2025 ESMO - European Society for Medical Oncology. We’re proud to share updated clinical results from our ongoing STARt-001 Phase 1/2 trial as we continue advancing this novel treatment for patients. A huge thank you to our presenter Elena Elez Fernández, MD PhD, and our strategic advisors Aparna Parikh, Michel Ducreux, Scott Kopetz, Josep Tabernero MD, PhD, and Elena Garralda Cabanas for their invaluable guidance and expertise in developing Invikafusp alfa in GI cancers. More details in the press release here: https://lnkd.in/eZjmcUjH #Oncology #GIcancer #Immunotherapy #ESMOGI2025 #MarengoTherapeutics #InnovationInImmunology #ClinicalResearch

🏃♀️🏃♂️ The Marengo Therapeutics team spirit was in full stride this week for the J.P. Morgan Corporate Challenge 5K in Boston! With our team of runners and walkers, almost every function at Marengo was represented at the event… we took part up not just as colleagues, but as a community supporting one another throughout. A huge shout out to our fearless team for bringing the energy, and to the organizers for an amazing event that celebrates wellness, camaraderie, and connection… See you at the start line next year! #JPMCC #BiotechStrong #RunMarengoRun #SciencewithSoles

We're #hiring a new Director, Portfolio Finance – Clinical Programs in Cambridge, Massachusetts. Apply today or share this post with your network.